



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>A61K 31/57, 7/48, 31/56</b>		A1	(11) International Publication Number: <b>WO 00/24401</b> (43) International Publication Date: <b>4 May 2000 (04.05.00)</b>
(21) International Application Number: <b>PCT/GB99/03472</b> (22) International Filing Date: <b>20 October 1999 (20.10.99)</b>		(74) Agent: CRAWLEY, Karen; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).	
(30) Priority Data: <b>9823036.0</b> 22 October 1998 (22.10.98) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(72) Inventors; and (75) Inventors/Applicants (for US only): DOW, Gordon, J. [US/US]; Dow Pharmaceutical Science, 1330A Redwoodway, Petaluma, CA 94954 (US). JOHNSON, Keith, Arthur [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). KELLY, Frances, Furr [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). LATHROP, Robert, William [US/US]; Dow Pharmaceutical Science, 1330A Redwoodway, Petaluma, CA 94954 (US). RAJAGOPALAN, Rukmini [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).	
<p><b>Published</b>  <i>With international search report.</i></p>			
<p><b>(54) Title:</b> FLUTICASONE LOTION HAVING IMPROVED VASOCONSTRICTOR ACTIVITY</p>			
<p><b>(57) Abstract</b></p> <p>A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.</p>			